Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vaxart Inc (VXRT)
NASDAQ:VXRT
VXRT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.52 - $1.54
Previous CloseN/A
Volume1.40M
Average Volume (3M)2.12M
Market Cap
$178.57M
Enterprise Value$157.47M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Feb 20, 2025EPS Estimate
-0.1Last Dividend Ex-Date
Nov 09, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding227,479,810
10 Day Avg. Volume1,412,942
30 Day Avg. Volume2,121,626
Standard Deviation0.57
R-Squared0.00327
Alpha0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.65
Price to Cash Flow (P/CF)-10.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.59
Enterprise Value/Ebitda-2.48
Forecast
1Y Price Target
$3.25Price Target Upside364.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Vaxart News
PremiumCompany Announcements
Vaxart Announces Board Changes with New Appointment
PremiumCompany Announcements
Vaxart’s Q3 2024: Progress in Oral Vaccine Development---
Bulls Say, Bears Say
Bulls Say
BARDA FundingVaxart received a BARDA-funded project NextGen award of up to $453M to conduct a large-scale study for its oral COVID-19 vaccine candidate.
Norovirus Market OpportunityNorovirus is an attractive market with VXRT now leading the way, as there's currently no approved norovirus vaccine, making the opportunity highly attractive.
Oral Vaccine PlatformAnalyst's recommendation to initiate coverage of VXRT with an Outperform rating is driven by optimism on VXRT's differentiated oral vaccine platform and key programs advancing oral norovirus and COVID-19 vaccines.
Bears Say
Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.
Potential Stock DilutionThe increase in the price target from $2.00 to $2.50 reflects subsidizing of planned R&D spend and potential dilution from a follow-on offering.
Regulatory ChallengesManagement is in ongoing active discussions with the FDA, highlighted by a recent Type C meeting, to clarify potential late-stage development, which could expedite the path to market.
---
Ownership Overview
1.04% Insiders
5.19% Mutual Funds
0.02% Other Institutional Investors
89.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VXRT FAQ
What was Vaxart Inc’s price range in the past 12 months?
Vaxart Inc lowest stock price was $0.52 and its highest was $1.54 in the past 12 months.
What is Vaxart Inc’s market cap?
Vaxart Inc’s market cap is $178.57M.
When is Vaxart Inc’s upcoming earnings report date?
Vaxart Inc’s upcoming earnings report date is Feb 20, 2025 which is in 15 days.
How were Vaxart Inc’s earnings last quarter?
Vaxart Inc released its earnings results on Nov 13, 2024. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.04.
Is Vaxart Inc overvalued?
According to Wall Street analysts Vaxart Inc’s price is currently Undervalued.
Does Vaxart Inc pay dividends?
Vaxart Inc pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart Inc dividends here
What is Vaxart Inc’s EPS estimate?
Vaxart Inc’s EPS estimate is -0.1.
How many shares outstanding does Vaxart Inc have?
Vaxart Inc has 227,479,810 shares outstanding.
What happened to Vaxart Inc’s price movement after its last earnings report?
Vaxart Inc reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -11.268%.
Which hedge fund is a major shareholder of Vaxart Inc?
Among the largest hedge funds holding Vaxart Inc’s share is Graham Capital Management, L.P.. It holds Vaxart Inc’s shares valued at 18K.
---
Vaxart Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.25 (364.29% Upside)
$3.25 (364.29% Upside)
Hedge Fund Trend
Increased
By 20.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.24%
12-Months-Change
Fundamentals
Return on Equity
-105.69%
Trailing 12-Months
Asset Growth
57.77%
Trailing 12-Months
Company Description
Vaxart Inc
Biota Holdings Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.
---
VXRT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the company's COVID-19 oral vaccine program with strong funding and partnership with BARDA, along with notable revenue growth. However, challenges remain in the norovirus program with the need for additional data as requested by the FDA. Overall, the positive developments in the COVID-19 and HPV programs, alongside revenue growth, present an optimistic outlook.Read More>---
VXRT Stock 12 Month Forecast
Average Price Target
$3.25
▲(364.29% Upside)
Technical Analysis
Best Analysts Covering VXRT
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
-5.99%
reiterated a buy rating 3 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -5.99% per trade.
---